CD19-directed CAR-T cells

BIOLOGICAL2 trials

Sponsors

Shanghai Tongji Hospital, Tongji University School of Medicine, Peking Union Medical College Hospital

Conditions

B-cell Non-Hodgkin LymphomaLeukemiaLymphoma

Phase 1

CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy

Shanghai Tongji Hospital, Tongji University School of MedicineLeukemia, Lymphoma

Start: 2015-07-31End: 2020-06-30Target: 60Updated: 2018-12-03

A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects

CompletedNCT03483688

Peking Union Medical College HospitalB-cell Non-Hodgkin Lymphoma

Start: 2018-03-06End: 2020-01-10Updated: 2020-03-05

Related Papers

Characterization of Hemophagocytic Lymphohistio(HLH）in Relapsed Diffuse Large B-Cell Lymphoma Patients after CAR-T Therapy

Blood2023-11-021 citations

The Efficacy and Safety of Decitabine Combined with Fludarabine and Cyclophosphamide As Conditioning Regimen in Second CD19 CAR-T Infusion

Blood2023-11-02

Radiotherapy Combined Chimeric Antigen Receptor T-Cells Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma（R/R DLBCL）

Blood2023-11-02

Development and Validation of a Clinical Prediction Model for the Efficacy of CD19 CAR T-Cell Therapy in DLBCL

Blood2023-11-02

[Anti-CD19 CART (C-CAR011) Therapy for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma].

PubMed2021-08-01